These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 13931194)

  • 21. Stop flow analysis of aldosterone and steroidal antagonist SC-8109 on renal tubular sodium transport kinetics.
    VANDER AJ; WILDE WS; MALVIN RL
    Proc Soc Exp Biol Med; 1960 Mar; 103():525-7. PubMed ID: 13841216
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors.
    Funder JW; Feldman D; Highland E; Edelman IS
    Biochem Pharmacol; 1974 May; 23(10):1493-501. PubMed ID: 4367952
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of spironolactone in renal edema. Effectiveness and association with hyperkalemia.
    MANNING RT; BEHRLE FC
    JAMA; 1961 Jun; 176():769-71. PubMed ID: 13766245
    [No Abstract]   [Full Text] [Related]  

  • 24. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology.
    Delyani JA
    Kidney Int; 2000 Apr; 57(4):1408-11. PubMed ID: 10760075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart.
    Barbato JC; Rashid S; Mulrow PJ; Shapiro JI; Franco-Saenz R
    Hypertension; 2004 Nov; 44(5):751-7. PubMed ID: 15466666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [THE MODES OF RENAL ACTION OF ALDOSTERONE INHIBITORS. DEDUCTIONS CONCERNING THE POINTS OF ATTACK OF ALDOSTERONE AT THE LEVEL OF THE KIDNEY].
    ROMANI JD; BERNHEIM R; GOOSENS F
    Ann Endocrinol (Paris); 1963; 24():588-97. PubMed ID: 14051313
    [No Abstract]   [Full Text] [Related]  

  • 27. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
    Preston RA; Afshartous D; Garg D; Medrano S; Alonso AB; Rodriguez R
    Hypertension; 2009 May; 53(5):754-60. PubMed ID: 19307466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal aldosterone receptors: studies with (3H)aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304).
    Marver D; Stewart J; Funder JW; Feldman D; Edelman IS
    Proc Natl Acad Sci U S A; 1974 Apr; 71(4):1431-5. PubMed ID: 4364539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of aldosterone on renin release in the isolated bloodless perfused canine kidney.
    Greco JM; Murphy GP
    Invest Urol; 1972 Jan; 9(4):294-9. PubMed ID: 5058768
    [No Abstract]   [Full Text] [Related]  

  • 30. Preparation of metabolites of spironolactone by microbial oxygenation.
    Marsheck WJ; Karim A
    Appl Microbiol; 1973 Apr; 25(4):647-9. PubMed ID: 4699222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
    Nielsen FT; Jensen BL; Marcussen N; Skøtt O; Bie P
    Nephrol Dial Transplant; 2008 Sep; 23(9):2777-83. PubMed ID: 18424460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.
    Luther JM; Gainer JV; Murphey LJ; Yu C; Vaughan DE; Morrow JD; Brown NJ
    Hypertension; 2006 Dec; 48(6):1050-7. PubMed ID: 17043157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.
    Ramsay LE; Hessian P; Tidd MJ
    Br J Clin Pharmacol; 1975 Jun; 2(3):271-6. PubMed ID: 1234508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a spirolactone (SC-8109) in primary mineralocorticoid excess.
    KISTLER H; FRAWLEY TF
    J Clin Endocrinol Metab; 1960 Aug; 20():1158-67. PubMed ID: 14409470
    [No Abstract]   [Full Text] [Related]  

  • 35. Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives.
    Kamata S; Matsui T; Haga N; Nakamura M; Odaguchi K; Itoh T; Shimizu T; Suzuki T; Ishibashi M; Yamada F
    J Med Chem; 1987 Sep; 30(9):1647-58. PubMed ID: 3040999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of aldosterone antagonism in the treatment of edema and ascites.
    GANTT CL; ECKLUND RE
    Am J Med; 1962 Oct; 33():490-500. PubMed ID: 13946423
    [No Abstract]   [Full Text] [Related]  

  • 37. [A study of the natriuretic action of an antagonist of aldosterone: spirolactone SC 9420 (aldactone)].
    VEYRAT R; ENGEL E; DUCOMMUN P; MULLER AF
    Schweiz Med Wochenschr; 1960 Apr; 90():494-7. PubMed ID: 13842023
    [No Abstract]   [Full Text] [Related]  

  • 38. [Study of the metabolic effects of the spirolactone SC 9420 in man].
    ROMANI JD; KELLER A
    Ann Endocrinol (Paris); 1961; 22():357-66. PubMed ID: 13742998
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of aldosterone and spirolactone on urinary sodium and potassium excretion in newborns and infants (author's transl)].
    Solc J; Knorr D
    Z Kinderheilkd; 1974 Jan; 116(2):143-52. PubMed ID: 4816159
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of aldosterone blockade in resistant hypertension.
    Egan BM; Li J
    Semin Nephrol; 2014 May; 34(3):273-84. PubMed ID: 25016399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.